[1]刘维帅,郭晓宁,杨 洋,等.胃癌病理类型及临床预后与血清miR-133a和DKK-1相关性分析[J].陕西医学杂志,2020,49(6):751-754.[doi:DOI:10.3969/j.issn.10007377.2020.06.028]
　LIU Weishuai,GUO Xiaoning,YANG Yang,et al.Correlation of pathological types and clinical prognosis of gastric cancer with serum miR-133a and DKK-1[J].,2020,49(6):751-754.[doi:DOI:10.3969/j.issn.10007377.2020.06.028]
点击复制

胃癌病理类型及临床预后与血清miR-133a和DKK-1相关性分析
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年6期
页码:
751-754
栏目:
临床病理
出版日期:
2020-06-05

文章信息/Info

Title:
Correlation of pathological types and clinical prognosis of gastric cancer with serum miR-133a and DKK-1
作者:
刘维帅; 郭晓宁; 杨 洋; 张娟娣△
陕西省杨凌示范区医院病理科(杨凌 712100)
Author(s):
LIU Weishuai; GUO Xiaoning; YANG Yang; et al.
Department of Pathology,Yangling Demonstration Zone Hospital,Shaanxi Province(Yangling 712100)
关键词:
胃癌;  血清miR-133a;  血清DKK-1;  胃癌病理类型;  临床预后;  相关性
Keywords:
Gastric cancer;  Serum miR-133a;  Serum DKK-1;  Pathological type of gastric cancer;  Clinical prognosis;  Correlation
分类号:
R446.8
DOI:
DOI:10.3969/j.issn.10007377.2020.06.028
文献标志码:
A
摘要:
目的:探讨胃癌患者血清中miR-133a和DKK-1水平与胃癌病理类型及临床预后的相关性。方法:选取经病理检查确诊为胃癌患者84例,分析不同病理分型、病理分期、有无淋巴结转移及不同细胞分化程度下血清中miR-133a、DKK-1水平。结果:miR-133a在乳头状腺癌、黏液腺癌、低分化腺癌及腺鳞癌患者中显著降低(P<0.05),DKK-1在乳头状腺癌、黏液腺癌、低分化腺癌及腺鳞癌患者中均显著升高(P<0.05); TNM分期Ⅳ期中DKK-1最高、miR-133a最低,TNM分期Ⅰ期中DKK-1最低、miR-133a最高,DKK-1随TNM分期加重显著上升(P<0.05),而miR-133a随TNM分期增加而显著下降(P<0.05); 淋巴结转移胃癌患者中的DKK-1显著高于无淋巴结转移的胃癌患者(P<0.05),淋巴结转移的胃癌患者中miR-133a显著低于无淋巴结转移的胃癌患者(P<0.05); 不同细胞分化胃癌患者中低分化DKK-1水平最高、miR-133a水平最低,高分化DKK-1水平最低、miR-133a水平最高,DKK-1水平随T细胞分化程度增强显著下降(P<0.05),miR-133a水平随细胞分化程度增强显著上升(P<0.05); DKK-1及miR-133a在不同预后结局中的表达存在差异,胃癌死亡患者DKK-1水平高于存活超过2年的胃癌患者(P<0.05),胃癌死亡患者miR-133a水平低于存活超过时间2年的胃癌患者(P<0.05)。结论:胃癌患者血清中miR-133a、DKK-1水平与胃癌患者的病理分期、病理分型、有无转移及细胞分化程度之间有着密切联系,可以通过检测血清中miR-133a、DKK-1水平对胃癌患者疾病的进展情况进行初步诊断。
Abstract:
Objective:To investigate the correlation of pathological types and clinical prognosis of gastric cancer with serum miR-133a and DKK-1.Methods:84 patients with gastric cancer confirmed by pathological examination were selected to analyze the levels of miR-133a and DKK-1 in serum of patients with gastric cancer under different pathological types,pathological stages,lymph node metastasis and cell differentiation.Results:MiR-133a was significantly decreased significantly in patients with papillary adenocarcinoma,mucinous adenocarcinoma,poorly differentiated adenocarcinoma and adenosquamous carcinoma,and DKK-1 was significantly increased in patients with papillary adenocarcinoma,mucinous adenocarcinoma,poorly differentiated adenocarcinoma and adenosquamous carcinoma.DKK-1 was the highest and miR-133a was the lowest in TNM stage Ⅵ,and DKK-1 was the lowest and miR-133a was the highest in TNM stage Ⅰ.DKK-1 was increased significantly with TNM stage aggravation,while miR-133a was decreased significantly with TNM stage aggravation.DKK-1 in patients with lymph node metastasis was significantly higher than that in patients without lymph node metastasis,and miR-133a in patients with lymph node metastasis was significantly lower than that in patients without lymph node metastasis.In patients with poorly differentiated gastric cancer,the level of DKK-1 was highest,and the level of miR-133a was lowest.In patients with highly differentiated gastric cancer,the level of DKK-1 was lowest,and the level of miR-133a was highest.The level of DKK-1 was decreased significantly with the increase of T cell differentiation,and the level of miR-133a was increased significantly with the increase of T cell differentiation.The expression of DKK-1 and miR-133a in different prognosis outcome was different,and the level of DKK-1 in dead gastric cancer patients was higher than that of gastric cancer pa-tients who survived for more than 2 years,while the level of miR-133a in dead gastric cancer patients was lower than that of gastric cancer patients who survived for more than 2 years.Conclusion:The levels of miR-133a and DKK-1 in the serum of patients with gastric cancer are closely related to the pathological stage,pathological classification,lymph node metastasis and cell differentiation degree of patients with gastric cancer.It can be preliminarily determined by detecting the levels of miR-133a and DKK-1 in the serum of patients with gastric cancer.

参考文献/References:

[1] Classen YHM,de Steur WO,Hartgrink HH,et al.Surgicopathological quality control and protocol adherence to lymphadenectomy in the CRITICS gastric cancer trial[J].Annals of Surgery,2018,268(6):1008-1013.
[2] 毛智军,王建华,宋 斌,等.胃癌患者血清肿瘤异常蛋白检测的临床意义[J].陕西医学杂志,2017,46(7):976-978.
[3] 宋 军,龚 宇,汤黎明,等.胃癌患者血清中miR-133a水平及其与病理特征的相关性[J].中国肿瘤生物治疗杂志,2017,24(12):1409-1413.
[4] 王延峰,米志宽,张华华,等.血清蛋白组与消化道恶性肿瘤研究进展[J].陕西医学杂志,2017,46(11):1619-1620.
[5] Polom K,Marrelli D,Roviello G,et al.Single center experience on anatomy-and histopathology-based gastric cancer molecular classification[J].Cancer Investigation,2017,35(26):325-332.
[6] 王雅坤,沈 琳,张小田.70例血清甲胎蛋白升高晚期胃癌患者的临床病理特征及预后[J].中华肿瘤杂志,2017,39(7):514-517.
[7] Ahn S,Lee SJ,Kim Y,et al.High-throughput protein and mrna expression-based classification of gastric cancers can identify clinically distinct subtypes,concordant with recent molecular classifications[J].American Journal of Surgical Pathology,2017,41(1):106-115.
[8] 薛卫成,樊祥山,孟 刚.胃癌相关标志物免疫组化指标选择专家共识[J].临床与实验病理学杂志,2014(9):951-953.
[9] Owen GI,Pinto MP,Retamal IN,et al.Chilean gastric cancer task force:a study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients[J].Medicine,2018,97(16):e0419-e0421.
[10] 李镇伽,徐苏鸣,陈若溪,等.Flotillin-2在胃癌组织中的表达及其临床意义[J].中国肿瘤生物治疗杂志,2018,25(6):629-633.
[11] Kang SH,Lee Y, Min SH,et al.Multimodal enhanced recovery after surgery(ERAS)program is the optimalperioperative care in patients undergoing totally laparoscopic distal gastrectomy for gastric cancer:a prospective,randomized,clinical trial[J].Annals of Surgical Oncology,2018,25(11):3231-3238.
[12] 常 青.胃癌根治术后影响预后的相关因素分析[J].陕西医学杂志,2017,46(8):1041-1042.
[13] Fujiya K,Kawamura T,Omae K,et al.Impact of malnutrition after gastrectomy for gastric cancer on long-term survival[J].Annals of Surgical Oncology,2018,25(4):974-983.
[14] 王小强,常家聪,叶啸天,等.人胃癌组织BRSK2表达与患者临床病理学参数及预后的关系[J].安徽医科大学学报,2017,23(9):1346-1351.
[15] 张大川,鲁常青,李 青,等.胃癌组织中肿瘤浸润淋巴细胞与临床病理特征的相关性及预后的影响[J].中华实验外科杂志,2017,34(2):205-207.
[16] Shen Y,Chen F,Liang Y.MicroRNA-133a inhibits the proliferation of non-small cell lung cancer by targeting YES1[J].Oncology Letters,2019,18(6):6759-6765.

相似文献/References:

[1]侯洁心 ,郭萍△.免疫组化标志物Her2和肿瘤标志物在胃癌诊断中的价值分析*[J].陕西医学杂志,2019,(1):121.
　HOU Jiexin,GUO Ping..The value of immunohistochemical marker Her2 andtumor markers in the diagnosis of gastric cancer[J].,2019,(6):121.
[2]唐亚荣.循环热灌注化疗联合替吉奥及热疗治疗老年胃癌癌性腹水临床研究*[J].陕西医学杂志,2019,(4):435.
　TANG Yarong..Clinical effect analysis of combined therapy with tiago and hyperthermia in the treatment of malignant ascites in elderly patients with gastric cancer[J].,2019,(6):435.
[3]刘国庆,闫 龙△,高 任.1.5T磁共振扩散加权成像在胃癌淋巴结转移诊断中的应用价值*[J].陕西医学杂志,2019,(4):456.
　LIU Guoqing,YAN Long,GAO Ren..1.5T magnetic resonance diffusion weighted imaging in the diagnosis of lymph node metastasis of gastric cancer[J].,2019,(6):456.
[4]胡乃军,王海龙.胃腺癌组织中MMP11、MMP12和VEGFD的表达及临床意义[J].陕西医学杂志,2019,(5):554.
[5]米志宽,赵菊梅.抑癌基因甲基化与胃癌关系研究进展*[J].陕西医学杂志,2019,(5):679.
　MI Zhikuan,ZHAO Jumei..Research progress of relationships between tumor suppressor gene methylation and gastric cancer[J].,2019,(6):679.
[6]石颖鹏,王敏娟,李程亮.肠化生相关分子与胃癌的发生和进展研究概况[J].陕西医学杂志,2019,(7):958.
　SHI Yingpeng,WANG Minjuan,LI Chengliang,et al.Intestinal metaplasia-related molecules and the occurrence and progress of gastric cancer[J].,2019,(6):958.
[7]郭小艳,于桂萍.抗幽门螺杆菌疗法联合新辅助化疗对胃癌术后疗效及患者血清VEGF、bFGF的影响[J].陕西医学杂志,2019,(8):1010.
　GUO Xiaoyan,YU Guiping..Effect of anti-Helicobacter pylori therapy combined with neoadjuvant chemotherapy on serum VEGF and bFGF in postoperative patients with gastric cancer[J].,2019,(6):1010.
[8]柯东平,毛俊倩,郭甲民,等.SCNN1B与胃癌细胞上皮间质转化相关性实验研究*[J].陕西医学杂志,2019,(9):1115.
　KE Dongping,MAO Junqian,GUO Jiamin,et al.Research on the correlation between SCNN1B and〖JZ〗 epithelialmesenchymal transformation in gastric cancer cells[J].,2019,(6):1115.
[9]王小林,马任远,张 哲.腹腔镜手术治疗老年进展期胃癌50例临床疗效分析[J].陕西医学杂志,2019,(10):1360.
[10]张 铭,张新望,艾 静,等.胃癌患者血浆微小RNA-100表达水平及其临床意义*[J].陕西医学杂志,2020,49(7):893.[doi:DOI:10.3969/j.issn.10007377.2020.07.034]
　ZHANG Ming,ZHANG Xinwang,AI Jing,et al.Study on expression level of microRNA-100 in plasma of patients with gastric cancer[J].,2020,49(6):893.[doi:DOI:10.3969/j.issn.10007377.2020.07.034]

更新日期/Last Update: 2020-07-28